Fact Sheet: Indian Health Service and Military Medical Prescription Drug Monitoring Program Requirements

Prescription Drug Monitoring Programs (PDMPs) can help clinicians improve decisions regarding opioid prescribing. However, since state laws and regulations governing access to these systems often apply only to providers licensed in the states in which the PDMP is located, and many federal health care workers are not so licensed, many federal providers are not subject to requirements. This fact sheet outlines the policies of the three federal health care institutions with regard to the use of PDMPs when prescribing opioids.

April 30, 2018

The Opioid Epidemic: From Evidence to Impact

Released October 2017. Prepared by the Johns Hopkins Bloomberg School of Public Health and the Clinton Foundation, Clinton Health Matters Initiative.

EXECUTIVE SUMMARY EXCERPT

November 13, 2017

Opioid Surveillance Webinar Series #2: Challenges and Implications of Postmarketing Surveillance of Prescription Opioids

This is the second installment of the ISDS Opioid Surveillance Webinar Series, June - July, 2017. Click here for Part 1 of the Opioid Surveillance Webinar Series and here for Part 3.

 

June 29, 2017

Builiding Methods for a Proactive Prescription Drug Surveillance System

Prescription Drug Monitoring Programs (PDMPs) are operating in 49 states and several U.S. territories.

June 08, 2017

Using Health Information Exchange to Improve Use of Prescription Monitoring Data

Washington State experienced a five-fold increase in deaths from unintentional drug overdoses between 1998 and 2014. The PMP collects data on controlled substances prescribed to patients and makes the data available to healthcare providers, giving providers another tool for patient care and safety. Optimal impact for the program depends on providers regularly accessing the information to review patients’ dispensing history.

March 14, 2017

CDC June 2016 Community of Practice Webinar Recording

Drs. Arens, Vo, van Wijk, and Coffin will present a cluster of opioid-related poisoning cases and deaths in San Francisco following ingestion of counterfeit pills designed to look like prescription medication. They will describe the clinical cases and detailed the coordinated public health response, which included the local PCC, a toxicology lab, a public health officer, the local medical examiner, and affected hospitals.

Presenters:

Ann Arens, MD and Kathy Vo, MD, Medical Toxicology Fellows, California Poison Control System, San Francisco Division 

April 10, 2017

Antiviral Prescription Data to Enhance Influenza Surveillance

Influenza surveillance provides public health officials and healthcare providers with data on the onset, duration, geographic location, and level of influenza activity in order to guide the local use of interventions. The Influenza Sentinel Provider Surveillance Network tracks influenza-like illness (% ILI) across the U.S. population. Objective: This presentation describes the use of influenza antiviral data from retail pharmacies to supplement influenza surveillance.

July 30, 2018

Chronic Pain Syndrome - Kansas Board of Pharmacy

This is a preliminary Chronic Pain-Related Syndrome, created to search relevant ICD10 and a few key terms in emergency department visits in ESSENCE. The codes and terms are specific to non-cancer related chronic pain with exclusions of cases receiving cancer-related ICD10.

ICD10 codes were selected by translating the following ICD9 codes for Chronic Pain contained in this PDF (https://www.cdc.gov/drugoverdose/pdf/pdo_guide_to_icd-9-cm_and_icd-10_co...)

May 04, 2018

Contact Us

NSSP Community of Practice

Email: syndromic@cste.org

 

This website is supported by Cooperative Agreement # 6NU38OT000297-02-01 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health between the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. CDC is not responsible for Section 508 compliance (accessibility) on private websites.

Site created by Fusani Applications